Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stroke (CVA) or Transient Ischemic Attack Clear all
Completed Not applicable Interventional

The PREVENTS Trial: The Preventing Recurrent Events in Veterans Navigating Transient Ischemic Attack (TIA) or Stroke Trial

NCT01020851
View directory record Official record
Conditions
Stroke, Transient Ischemic Attack
Interventions
tailored intervention, attention placebo
Behavioral
Lead sponsor
Narrows Institute for Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Jul 21, 2026, 9:29 AM EDT
Not listed Phase 2Phase 3 Interventional

Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)

NCT00201461
View directory record Official record
Conditions
Patent Foramen Ovale, Stroke, Ischemic Attack, Transient
Interventions
STARFlex septal closure system, Best medical therapy
Device · Drug
Lead sponsor
NMT Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2008 · Synced Jul 21, 2026, 9:29 AM EDT
Completed Not applicable Interventional Results available

GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients

NCT00738894
View directory record Official record
Conditions
Stroke, Transient Ischemic Attack
Interventions
Septal Occluder Device, Antiplatelet Medical Therapy
Device · Drug
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years to 60 Years
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Jul 21, 2026, 9:29 AM EDT
Recruiting No phase listed Observational

Natural History of Stroke: Cause and Development

NCT00009243
View directory record Official record
Conditions
Brain Disease, Ischemic Attack, Transient, Cerebrovascular Accident, Cerebrovascular Disorder, Vascular Diseases
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 9:29 AM EDT
Completed Phase 3 Interventional

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

NCT05686070
View directory record Official record
Conditions
Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke, High-risk Transient Ischemic Attack
Interventions
Asundexian (BAY2433334), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
12,327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
108
States / cities
Fairhope, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 21, 2026, 9:29 AM EDT
Not yet recruiting Phase 3 Interventional

Cilostazol for Prevention of Recurrent Stroke Trial

NCT07174414
View directory record Official record
Conditions
Stroke Recurrence, Myocardial Infarction, Vascular Death, Ischemic Stroke, TIA (Transient Ischemic Attack), Stroke (CVA) or Transient Ischemic Attack, Recurrent Stroke
Interventions
Cilostazol 100 mg, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
40 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 21, 2026, 9:29 AM EDT
Recruiting Not applicable Interventional

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

NCT06943586
View directory record Official record
Conditions
Stroke, Transient Ischemic Attack (TIA)
Interventions
CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
Genetic
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 21, 2026, 9:29 AM EDT
Completed Not applicable Interventional

Targeted Management Intervention for African-American Men With TIA or Stroke

NCT01807793
View directory record Official record
Conditions
Stroke, Transient Ischemic Attack (TIA)
Interventions
Psychoeducation
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
22 Years to 64 Years · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 21, 2026, 9:29 AM EDT
Active, not recruiting Not applicable Interventional

Video-based Intervention to Address Disparities in Blood Pressure Control After Stroke

NCT05264298
View directory record Official record
Conditions
Stroke
Interventions
VIRTUAL, Standard care
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jul 21, 2026, 9:29 AM EDT
Terminated Not applicable Interventional

Motivational Interviewing for Stroke

NCT06195007
View directory record Official record
Conditions
Acute Stroke, Transient Ischemic Attack
Interventions
Motivational Interview
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Jul 21, 2026, 9:29 AM EDT
Not listed Early Phase 1 Interventional

Lovaza's Effect on Clopidogrel in a Neuro Population

NCT01526824
View directory record Official record
Conditions
Ischemic Stroke, Transient Ischemic Attack
Interventions
omega-3 polyunsaturated fatty acids (Lovaza)
Dietary Supplement
Lead sponsor
Millard Fillmore Gates Hospital
Other
Eligibility
25 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2012 · Synced Jul 21, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

NCT01344447
View directory record Official record
Conditions
Carotid Stenosis
Interventions
Gadobutrol (Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Tucson, Arizona • Jacksonville, Florida • Savannah, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Jul 21, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

NCT01994720
View directory record Official record
Conditions
Acute Ischaemic Stroke, Transient Ischaemic Attack
Interventions
ticagrelor, Acetylsalicylic acid (ASA)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
13,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
115
States / cities
Montgomery, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 112 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Jul 21, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

NCT02671461
View directory record Official record
Conditions
Thrombosis
Interventions
BMS-986141, Aspirin, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
27
States / cities
Phoenix, Arizona • Newport Beach, California • Newark, Delaware + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Jul 21, 2026, 9:29 AM EDT
Recruiting Phase 4 Interventional

Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes

NCT05780905
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack
Interventions
Semaglutide Auto-Injector, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
40 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Jul 21, 2026, 9:29 AM EDT
Recruiting Not applicable Interventional

Neuromodulation-Enhanced Use of RObotic BALANCE Training to Improve Balance Function in Individuals With Stroke

NCT07113041
View directory record Official record
Conditions
Stroke, Stroke (CVA) or Transient Ischemic Attack, Stroke Ischemic, Stroke Gait Rehabilitation, Balance Deficits
Interventions
Combined (Robotic balance training and high-definition transcranial direct current stimulation), Standard of Care Balance Training
Device · Other
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Jul 21, 2026, 9:29 AM EDT
Withdrawn Phase 1 Interventional

Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack

NCT00363753
View directory record Official record
Conditions
Transient Ischemic Attack, Stroke, Aspirin, Clopidogrel
Interventions
aspirin versus clopidogrel
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Jul 21, 2026, 9:29 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

NCT05702034
View directory record Official record
Conditions
Ischemic Stroke; Ischemic Attack, Transient
Interventions
Milvexian, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
40 Years and older
Enrollment
12,532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
127
States / cities
Mesa, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 102 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 9:29 AM EDT
Completed Not applicable Interventional

Improve Medication Adherence Among Stroke Survivors in Rural Kentucky

NCT07084051
View directory record Official record
Conditions
Stroke (CVA) or Transient Ischemic Attack
Interventions
I-MAS
Behavioral
Lead sponsor
Hend Mansoor
Other
Eligibility
30 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jul 21, 2026, 9:29 AM EDT
Terminated Phase 3 Interventional

Aspirin Or Warfarin To Prevent Stroke

NCT00004728
View directory record Official record
Conditions
Stroke, Cerebral Infarction, Atherosclerosis, Constriction, Pathologic
Interventions
Warfarin, Aspirin
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 5, 2006 · Synced Jul 21, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Results available

A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel

NCT03766581
View directory record Official record
Conditions
Acute Ischemic Stroke, Transient Ischemic Attack (TIA)
Interventions
BMS-986177, Placebo, Clopidogrel, Aspirin
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years and older
Enrollment
2,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
66
States / cities
Birmingham, Alabama • Glendale, California • Long Beach, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Jul 21, 2026, 9:29 AM EDT